Condition
Anakinra
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 4 (2)
Trial Status
Not Yet Recruiting1
Unknown1
Active Not Recruiting1
Terminated1
Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT05611710Phase 2Active Not Recruiting
Anakinra in Dengue With Hyperinflammation ( AnaDen )
NCT06624436Phase 4Recruiting
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
NCT06697431Phase 4Not Yet Recruiting
Non Inferiority KawasakI Trial With Anakinra
NCT03991520Early Phase 1Unknown
Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms
NCT01122914Phase 1TerminatedPrimary
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
Showing all 5 trials